Medicine and Pharmacology

Article
Medicine and Pharmacology
Urology and Nephrology

Michał Andrzej Skrzypczyk

,

Łukasz Białek

,

Marta Rydzińska

,

Anna Pliszka

,

Jakub Dobruch

,

Mikołaj Przydacz

Abstract: Background/Objectives: We compared functional outcomes and device survival at one and five years in men who received a ZSI 375 or AMS 800 artificial urinary sphincter (AUS) for stress urinary incontinence. Methods: We matched 36 ZSI 375 recipients to 36 AMS 800 recipients in a retrospective cohort of men undergoing implantation for stress urinary incontinence. Preoperative incontinence was severe in 70 men and moderate in two. The primary surgical outcome was time to first revision, including surgery on a single component. Device survival ended at complete removal or replacement. Social continence required use of 0–1 pad per day with the implanted sphincter in place and functioning. Results: During follow-up, 12/36 AMS 800 recipients and 14/36 ZSI 375 recipients underwent revision (hazard ratio for ZSI 375 vs. AMS 800, 0.64, 95% confidence interval 0.25–1.64). Estimated device survival was 86.0% versus 91.7% at one year and 71.0% versus 79.9% at five years (AMS 800 vs. ZSI 375). Social continence with a functioning device was achieved by 23/29 versus 13/29 men at one year (p = 0.013) and 12/16 versus 5/16 at five years (p = 0.039). When any surgical revision counted as failure, the one-year comparison was 21/29 versus 13/29 (p = 0.077). Conclusions: More men with an AMS 800 achieved social continence with a functioning sphincter at both assessments. The study could not establish which device was less likely to require revision. Nonrandom device selection and differences in implantation year limit attribution to device choice.

Case Report
Medicine and Pharmacology
Urology and Nephrology

Jessica Wirjosoenjoto

,

Olly Indrajani

,

Subagjo

Abstract: Background: Chronic kidney disease (CKD) is associated with oxidative stress, inflammation, and vascular dysfunction. Molecular hydrogen has been investigated as an adjunctive intervention, but clinical evidence for hydrogen–oxygen nanobubble (HHO) therapy in non-dialysis CKD remains limited. Methods: We describe a male patient with CKD G3b, hypertension, prediabetes, and previous long-term nonsteroidal anti-inflammatory drug exposure who presented on March 7, 2026. The records describe 12 HHO sessions (three weekly; reported volumes increasing from 5 to 25 mL) alongside standard care. Results: Historical estimated glomerular filtration rate (eGFR) was 33.6 mL/min/1.73 m² in March 2025, compared with 39 mL/min/1.73 m² on March 28, 2026; both values are within G3b. Peripheral perfusion index changed from 2.1 to 5.4, and blood pressure from 138/76 to 113/72 mmHg. The patient also reported resolution of recurrent morning rhinorrhea. The treatment dates relative to kidney-function testing were incompletely documented, and concomitant medication and measurement variability limit causal inference. Peripheral perfusion index does not directly measure renal perfusion. Conclusions: This case provides descriptive observations but cannot establish renal efficacy or safety of adjunctive HHO therapy. Prospective studies with standardized interventions, longitudinal renal measurements, and safety monitoring are needed.

Article
Medicine and Pharmacology
Urology and Nephrology

Kazuyoshi Okada

,

Manabu Tashiro

,

Hiroyuki Michiwaki

,

Daisuke Hara

,

Shimpei Araki

,

Ryo Mochizuki

,

Tomoko Inoue

,

Takahiro Kuragano

,

Jun Minakuchi

Abstract: Controlled hypoalbuminemia due to high albumin leakage (Alb-L) improves mortality in dialysis patients with mild weight loss and/or inflammation. However, no study has investigated whether it reduces mortality in old-old patients who tend to have progressively worsening hypoalbuminemia, weight loss, and inflammation over time. To address this question, this study retrospectively analyzed 227 dialysis patients aged ≥75 years who were classified into a high Alb-L group (≥3 g/session, n = 93) and a low Alb-L group (<3 g/session, n = 134). Propensity score matching was performed to compare 3-year all-cause mortality, yielding 93 matched patients in each group. In our facilities, hypoalbuminemia due to high Alb-L was acceptable down to serum Alb (S-Alb) of 3.0 g/dL in patients without overt weight loss and/or inflammation. Survival was assessed using Kaplan–Meier survival curves with patients censored when their Alb-L category changed during annual follow-up assessments. Mortality was significantly lower in the high Alb-L group than in the low Alb-L group (P = 0.007, log-rank test). Adjusted Cox proportional hazards regression analysis showed that mortality remained significantly lower in the high Alb-L group (adjusted hazard ratio [HR] 0.397, 95% confidence interval 0.184-0.859, P = 0.019). In a sensitivity analysis using the overlap weighting method in all 227 patients without censoring for changes in Alb-L category, the HR for high Alb-L remained below 1.0, but was not statistically significant relative to low Alb-L. In exploratory hypothesis-generating stratified subgroup analyses, body mass index (BMI) ≥20 kg/m2, high-sensitivity C-reactive protein (hs-CRP) level ≥0.3 mg/dL, and a group with BMI <22 kg/m2 and/or hs-CRP level ≥0.3 mg/dL were associated with lower mortality rates in high Alb-L than in low Alb-L, while no associations were observed for BMI <20 kg/m2, hs-CRP level <0.3 mg/dL, and a group with BMI ≥22 kg/m2 and hs-CRP <0.3 mg/dL. Although low Alb-L was associated with reduced S-Alb and BMI, and elevated serum creatinine (S-Cr) after 3 years, high Alb-L were associated with increased BMI, decreased S-Cr, and the prevention of reduced S-Alb level. Furthermore, in patients without inflammation, either high or low Alb-L was associated with elevated hs-CRP level after 3 years. In contrast, controlled hypoalbuminemia due to high Alb-L was associated with decreased hs-CRP level in patients with mild inflammation, but low Alb-L was not. Controlled hypoalbuminemia due to high Alb-L was associated with lower mortality relative to low Alb-L in exploratory analyses of patients aged ≥75 years with mild weight loss and/or inflammation.

Article
Medicine and Pharmacology
Urology and Nephrology

Kotaro Fukukawa

,

Kazuyoshi Shigehara

,

Rei Shinzawa

,

Hiroki Nakata

,

Naoaki Sakatoku

,

Shingo Takada

,

Yuki Kato

,

Shohei Kawaguchi

,

Takahiro Nohara

,

Kouji Izumi

+1 authors

Abstract: We investigated the anatomical distribution of human papillomavirus (HPV) infection in the lower urinary tract of men with bladder cancer undergoing radical cystectomy. In total, 79 anterior urethral samples, 99 prostatic urethral specimens, 74 bladder tumor specimens, and 87 non-tumor bladder specimens were collected from 102 patients. After DNA extraction from each formalin-fixed paraffin-embedded tissue specimen, HPV-DNA was examined by nested polymerase chain reaction, and HPV genotypes were determined by Sanger sequencing. In situ hybridization (ISH) was used to localize HPV-DNA in positive samples, and E6/E7 mRNA ISH was performed to assess transcriptional activity. HPV-DNA was detected at any site in 16 (15.7%) of 102 patients, with site-specific detection rates of 8.0% (7/87) in non-tumor bladder mucosa, 5.1% (4/79) in the anterior urethra, 4.1% (3/74) in bladder tumor tissue, and 4.0% (4/99) in the prostatic urethra. HPV16 was detected in 11 samples, and HPV18 in 7 samples. HPV-DNA ISH signals were observed in 12 (66.7%) of 18 HPV-positive specimens, and E6/E7 mRNA signals were present in 2 of 18 specimens. HPV-DNA was detected at various sites of the lower urinary tract. E6/E7 mRNA expression in a bladder cancer specimen warrants further research on the biological relevance of HR-HPV infection.

Article
Medicine and Pharmacology
Urology and Nephrology

Shingo Takada

,

Kazuyoshi Shigehara

,

Hiroki Nakata

,

Naoaki Sakatoku

,

Kotaro Fukukawa

,

Rei Shinzawa

,

Yuki Kato

,

Shohei Kawaguchi

,

Takahiro Nohara

,

Kouji Izumi

+1 authors

Abstract: This study investigated the prevalence, genotypes, and tissue localization of human papillomavirus (HPV)-DNA in testicular tumor including epididymis and spermatic cord specimens from 116 Japanese patients who underwent radical inguinal orchiectomy. Formalin-fixed, paraffin-embedded tissues were analyzed by nested polymerase chain reaction (PCR), followed by sequencing-based HPV genotyping. HPV-DNA localization was assessed by in situ hybridization (ISH), and E6/E7 mRNA ISH was performed in HPV-positive specimens. HPV-DNA was detected in three patients (3/116, 2.6%), including one testicular tumor specimen (1/116, 0.9%) and two spermatic cord specimens (2/116, 1.7%). All HPV-positive specimens contained HPV16-DNA. HPV-DNA ISH signals were observed in seminoma cells in one testicular specimen and in the vas deferens epithelium in one spermatic cord specimen. On the other hand, ISH signals were not present in epididymis tissue in the HPV-positive testicular tumor tissue, suggesting that HPV-DNA detection rate of epididymis was 0%. E6/E7 mRNA signals were not detected in any HPV-positive specimen. These findings demonstrate that HPV16-DNA was surely present in testicular tumor and the vas deferens epithelium. However we could not provide evidence of transcriptionally active HPV oncogenes, and could not establish a causal role in testicular tumorigenesis.

Article
Medicine and Pharmacology
Urology and Nephrology

Bennur Esen

,

Damla Yıldız

,

Khalida Baraki

,

Ahmet Engin Atay

Abstract: Background/ Objectives: Sodium–glucose cotransporter-2 inhibitors (SGLT2i) provide cardiorenal benefits beyond glucose lowering, yet longitudinal changes across multiple laboratory domains in patients with diabetic kidney disease (DKD) remain incompletely characterized. This study aimed to evaluate 12-month changes in renal, glycemic, metabolic, hematological, and inflammatory parameters in patients with DKD treated with empagliflozin or dapagliflozin. Methods: This retrospective, single-center cohort study included 452 patients with type 2 diabetes mellitus and DKD who received empagliflozin or dapagliflozin. Laboratory parameters were assessed at baseline and after 12 months. Longitudinal changes, between-group differences, correlations, and exploratory path analyses were evaluated. Results: Over 12 months, glycated hemoglobin and fasting glucose levels decreased, whereas estimated glomerular filtration rate (eGFR), vitamin D, hematocrit, mean corpuscular volume, and high-density lipoprotein cholesterol (HDL-C) increased. Ferritin, the triglyceride–glucose (TyG) index, bicarbonate, and plateletcrit decreased. Most other measured hematological and inflammatory parameters did not change significantly. The overall patterns of change were broadly similar between treatment groups, although selected differences were observed in individual parameters. In exploratory path analyses, age was negatively associated with change in eGFR (β = −0.269, p < 0.001), whereas KDIGO category was positively associated with change in eGFR (β = 0.200, p < 0.001). Sex was associated with change in the TyG index (β = −0.261, p = 0.013), and treatment group was associated with change in the platelet-to-lymphocyte ratio (β = −0.194, p = 0.010). The models explained a modest proportion of the variance. Conclusions: This real-world cohort provides a multidomain assessment of laboratory changes observed over 12 months in patients with DKD receiving empagliflozin or dapagliflozin. Changes extended beyond glycemic measures to selected renal, metabolic, and hematological parameters, while most conventional and composite inflammatory markers remained unchanged. The observational design and absence of a non-SGLT2i control group preclude causal conclusions or claims of long-term renoprotection. Prospective controlled studies are warranted to clarify the clinical significance and comparative effects of these changes.

Article
Medicine and Pharmacology
Urology and Nephrology

Sara Garach Fernández

,

Silvia García Barreras

,

Gema Martín Serrano

,

Guillermo Fernández Conejo

,

Francisco Javier Burgos Revilla

Abstract: Background/Objectives: To compare the perioperative, oncological and functional outcomes of the Versius® and DaVinci® systems as used for performing robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer. Methods: Prospective observational comparative study on 278 patients subjected to RARP between March 2023-September 2025. 169 procedures were performed with the Versius® system and 109 with the DaVinci® system. An analysis was performed of a series of demographic, perioperative, pathological and functional variables. Quantitative variables were compared using either Student’s t or the Mann-Whitney Test, while categorical variables were analyzed with the chi-squared test or Fisher’s Exact Test. Results: Both groups exhibited comparable baseline characteristics. No statistically significant differences were observed with respect to the amount of pelvic lymph nodes dissected, intraoperative or postoperative complications, transfusion requirements, length of hospital stay or postoperative PSA levels. DaVinci® was shown to be associated with higher rates of neurovascular bundle preservation (48.6% vs. 17.4%; p< 0.001) and the resection of a higher number of positive lymph nodes. Patients operated with the DaVinci® system were more likely to have pN1 disease (20% vs. 4.9%; p=0.014). No statistically significant differences were observed with respect to positive surgical margins, pT stage or the ISUP grade of the specimen. Urinary incontinence was more prevalent in the Versius® group at 3 and 6 months’ follow-up (p=0.003 y p=0.034, respectively), without significant differences at 12 months. Conclusions: Both Versius® and DaVinci® were shown to be safe and effective platforms for the performance of RARP, with comparable short-term perioperative and oncological outcomes.

Article
Medicine and Pharmacology
Urology and Nephrology

Shinji Lee

,

Denan Jin

,

Shinji Takai

Abstract: Background: Ischemia–reperfusion (I/R) injury is a major risk factor for the development of chronic kidney disease (CKD). However, effective treatments for preventing CKD progression following I/R injury have not yet been established. Methods: Mice underwent bilateral renal I/R injury and received continuous treatment with TY51469, a chymase-specific inhibitor. Renal injury and fibrosis were as-sessed six weeks after I/R. Blood urea nitrogen (BUN) levels, renal collagen deposition, mast cell ac-cumulation, mouse mast cell protease-4 (MMCP-4) expression, and the expression of fibrosis- and in-flammation-related genes were evaluated. Correlations between MMCP-4 and fibrosis- and inflamma-tion-related gene expression were also analyzed. Results: Six weeks after I/R injury, mice exhibited elevated BUN levels, increased renal collagen deposition, and upregulated expression of fibrosis- and inflammation-related genes, including transforming growth factor-beta 1 (TGF-β1), collagen I, matrix metalloproteinase-9 (MMP-9), and tumor necrosis factor-alpha (TNF-α). Mast cell accumulation and MMCP-4 expression were also markedly increased, particularly in fibrotic regions. Continuous treat-ment with TY51469 significantly attenuated BUN elevation, renal fibrosis, mast cell accumulation, MMCP-4 expression, and the upregulation of fibrosis- and inflammation-related genes. Furthermore, MMCP-4 expression was strongly positively correlated with the expression of TGF-β1, collagen I, MMP-9, and TNF-α. Conclusions: These findings suggest that mast cell-derived chymase contributes to renal fibrotic progression following I/R injury and that chymase inhibition may represent a poten-tial therapeutic strategy for preventing CKD development.

Article
Medicine and Pharmacology
Urology and Nephrology

Kirakoya Brahima

,

Ziba Ouima Justin Dieudonné

,

Ouedraogo Bénéwendé Landry Hugues

,

Traore Yannick Jean Rodrigue Pingdwindé

,

Ouedraogo Fato

,

Yameogo Clotaire Alexis Marie Kiemdiba Donega

,

Kabore Fasnewinde Aristide

Abstract: Background: Data on erectile dysfunction (ED) in young African men are scarce. We estimated ED prevalence among male university students in Ouagadougou, Burkina Faso, and examined associated factors, psychosocial impact, and help-seeking. Methods: In this cross-sectional online survey (January-July 2026), male students aged 18-30 years at Joseph Ki-Zerbo University completed an anonymous questionnaire. The five-item International Index of Erectile Function (IIEF-5) was scored in men who had attempted intercourse in the previous four weeks, with ED defined as a score of 21 or less. Associated factors were examined by multivariable logistic regression. Results: Of 696 respondents (mean age 24.1 ± 3.2 years), 476 were evaluable. ED was present in 240 (50.4%; 95% CI 45.9-54.9); it was mild in 151 and moderate or severe in 20. Self-reported depression (adjusted odds ratio 4.04; 95% CI 1.10-14.88) and other chronic conditions (1.87; 1.11-3.15) were independently associated with ED; age, alcohol, and tobacco use were not. Among men with ED, 66.5% reported interference with academic work, and only 11.9% of those acknowledging a problem had consulted a health professional. Shame was the most cited barrier (61.4%). Conclusions: Mostly mild ED was common in this sample and was linked to depression and chronic illness rather than lifestyle. Campus services should offer confidential sexual and mental health screening.

Article
Medicine and Pharmacology
Urology and Nephrology

Elena Emanuela Rusu

,

Teodor Căluşi

,

Bogdan Marian Sorohan

,

Dorina-Beatrice Tacu

,

Corina Țincu

,

Ruxandra-Oana Jurcuț

,

Robert Adam

,

Adriana Mursă

,

Diana-Silvia Zilişteanu

,

Bogdan Stănciulescu

+11 authors

Abstract: Fabry disease (FD) is a rare, X-linked, lysosomal storage multisystemic disorder which may lead to kidney failure and require kidney transplantation (KT). Data on long-term kidney allograft outcomes and the evolution of systemic FD under dis-ease-specific therapy after KT remain limited. We retrospectively evaluated six kidney transplant recipients (KTRs) with FD followed in our center for median tine after KT of 7 years (range, 4-13). Five patients (83.3%) were males and five had a classic Fabry phe-notype. At last follow-up patient survival was 100% and five out of six KTR had a func-tional kidney graft. Among KTRs with a functioning graft, the median change is esti-mated glomerular filtration rate from 1-year to last follow-up was +3.3 ml/min/1.73m2 (range, -50.7 to +10.5), while proteinuria remained low. One patient developed late an-tibody-mediated rejection with de novo donor-specific antibodies and graft loss at 8 years post-transplantation. Five KTRs were receiving enzyme replacement therapy at the time of KT. Three patients were subsequently switched to migalastat and two later returned to enzyme replacement therapy. Lyso-Gb3 and cardiac structural parameters showed heterogenous longitudinal trajectories despite generally preserved kidney graft function. No cardiovascular events occurred during follow-up. These findings support KT as an effective renal replacement therapy in FD and highlight the need for contin-uous Fabry-specific therapy and multidisciplinary surveillance after transplantation.

Review
Medicine and Pharmacology
Urology and Nephrology

Marcia Bastos Convento

,

Rodolfo Gabriel Pierre Marchi

,

Adelson Fernandes da Silva

,

Fernanda Teixeira Borges

Abstract: Background: Nanotechnology has expanded biomedical applications in chronic kidney disease (CKD), including diagnostics, monitoring, targeted therapy, and extracorporeal management. However, heterogeneity in materials, experimental models, and translational development complicates assessment of clinical progress. This review characterized major CKD nanotechnology applications and their documented translational stages, supported by complementary bibliometric analysis. Methods: English-language original studies indexed in PubMed/MEDLINE between July 1, 2021, and July 1, 2026, were organized into 11 overlapping thematic categories and classified according to their highest documented translational stage. Bibliometrix/Biblioshiny characterized publication, journal, institutional, and geographic patterns, while VOSviewer analyzed MeSH term co-occurrence. Results: Of 288 records identified, 160 studies across 91 journals were included. The most frequent categories were nanodiagnostics and biosensors (53 studies), nanotherapy for renal fibrosis (51), kidney-targeted drug delivery (28), and redox nanomedicine, inflammation, and oxidative stress (27). Diagnostic platforms more frequently reached human-sample validation or early clinical evaluation, whereas therapeutic approaches remained predominantly preclinical. Extracorporeal nanotechnologies were largely experimental, with limited human-sample evaluation. The 10 most productive journals accounted for 55 studies (34.4%), illustrating the concentration of publications within a multidisciplinary field. Conclusions: CKD nanomedicine exhibits substantial technological diversity but uneven translational development. Progress toward clinical implementation requires standardized physicochemical characterization, reproducibility, independent validation, long-term safety assessment, manufacturing scalability, and rigorous comparisons with established standards of care using clinically meaningful outcomes.

Article
Medicine and Pharmacology
Urology and Nephrology

Nailya A. Zigangirova

,

Dmitry Yu. Pushkar

,

Nataliya E. Bondareva

,

Nadezda L. Lubenec

,

Tamara S. Perepanova

,

Elena A. Smolyarchuk

,

Vladimir B. Beloborodov

,

Andrey V. Zaycev

,

Sergey K. Zyryanov

,

Maria A. Kareva

+3 authors

Abstract: Background/Objectives: New data on the pathogenesis of recurrent urinary tract infections (rUTIs) and the growing level of bacterial resistance to antibiotics require a revision of patient treatment strategies and a search for non-antibiotic approaches to the treatment and prevention of UTIs. The aim of this study was to investigate the clinical and microbiological efficacy of a new, non-traditional antibacterial drug, Fluorothiazinone (FT). Methods: We conducted an open-label, randomized, multicenter cohort clinical trial, phase III, at 12 hospitals in Moscow and St. Petersburg. 280 patients were randomized into two groups in a 1:1 ratio to receive FT at a dose of 1200 mg/day for 14 days or furadoninat a dose of 400 mg/day for 7 days. Clinical and microbiological cure were assessed 7, 14 and 28 days after the start of therapy. Results: For the primary efficacy end-point, clinical cure at day 28, the recovery rate was 91.7% in patients receiving FT and 92.8% in patients receiving furadonin, the hypothesis of non-inferiority of FT compared to the standard furadonin regimen was confirmed by two-sided 95% confidence intervals. The proportion of patients with clinical cure on days 7 and 14 also did not differ in the two groups. An assessment of microbiological eradication at all observation times in our study demonstrated that FT, whose mechanism of action is associated with the suppression of pathogen virulence, possesses antibacterial activity comparable to that of the antibiotic furadonin leading to the eradication of pathogens causing rUTIs. The frequency of microbiological relapses after 28 days of treatment was 19.6% in the group receiving FT and 22.2% in the group receiving furadonin. Both study groups were comparable in the severity of adverse events (AEs). A definite relationship with the study drugs was identified for 1 (11.1%) AEs after taking FT and 8 (88.9%) AEs after taking furadonin.Conclusions: Clinical trials in patients with recurrent cystitis have demonstrated the intrinsic antibacterial activity of FT, equal clinical and microbiological efficacy compared to first-line drugs for the treatment of recurrent cystitis, as well as a high level of safety, indicating the potential for the use of drugs with a new mechanism of action in the context of growing antibiotic resistance.

Article
Medicine and Pharmacology
Urology and Nephrology

Hippocrates Moschouris

,

Elena Hadjichristou

,

Apostolos Mouroukis

,

Maria-Theodora Moschouri

,

Konstantinos Stamatiou

,

Marios Ioannou

,

Dimitrios Kourdakis

,

Adam Hatzidakis

Abstract: Background/Objectives: Prostatic artery embolization (PAE) with n-butyl cyanoacrylate (NBCA) glue-lipiodol mixture has several advantages over PAE with microspheres for the treatment of symptomatic benign prostatic hyperplasia (BPH). However, distal penetration of glue-lipiodol in intraprostatic vasculature is often not possible and proximal-only prostatic artery (PA) occlusion with glue may fail to induce significant prostatic infarction. To mitigate this limitation, the authors applied and evaluated SEquential utilization of MIcrospheres and GLUE for PAE (SEMIGLUE-PAE). Meth-ods: For SEMIGLUE-PAE, embolization began with microspheres (100-300μm) with the microcatheter tip at the distal extraprostatic part of the PA; intraprostatic advancement of the microcatheter and injection of additional microspheres was then at-tempted. When flow stasis in intraprostatic branches was observed, embolization continued with small aliquots (0.1ml) of glue-lipiodol mixture (1:8) with the same initial position of microcatheter tip, until the distal one half (to two thirds) of the extraprostatic PA was filled with the mixture. SEMIGLUE-PAE was applied in 20 consecutive patients with symptomatic BPH. Short-term improvement in imaging and clinical parameters and safety were evaluated. Results: Clinical success rate was 95%, 90% and 83.6% at 3, 6 and 12 months post SEMIGLUE-PAE, respectively. Three months post SEMIGLUE-PAE, mean reduction of prostate volume was 32.4% (p< 0.01) and mean improvement of international prostate symptom score was 61.2% (p< 0.01). Mean percentage of prostatic infarction (measured within 24 hours post PAE and compared to baseline PV) was 45.7%. Minor (only) complications were encountered in 4/20 patients. Conclusions: SEMIGLUE-PAE seems to be safe, effective and feasible, especially for operators with limited experience in embolization with glue.

Article
Medicine and Pharmacology
Urology and Nephrology

Tatyana Simeonova

,

Borislav Ignatov

,

Tsvetelina Eftimova

,

Alexandar Blazhev

,

Krasimir Kostov

Abstract: Introduction: FGF23 and osteocalcin are important regulators of mineral and bone metabolism. The association between FGF23 and undercarboxylated osteocalcin (Glu-OC) in chronic kidney disease (CKD) remains insufficiently understood. This study aimed to investigate the association between FGF23 and Glu-OC and assess whether it is independent of kidney function. Methods: This cross-sectional study included 80 adults: 12 healthy controls and 68 patients with non-dialysis CKD stages G1–G4. FGF23, Glu-OC, calcium, phosphate, PTH, and bone metabolism markers were measured. Associations were assessed using Spearman correlation, partial Spearman correlation adjusted for eGFR, and multivariable linear regression. Results: FGF23 was inversely correlated with eGFR (ρ = −0.346; p = 0.004) and positively correlated with creatinine (ρ = 0.299; p = 0.013). FGF23 was inversely associated with Glu-OC (ρ = −0.344; p = 0.004), with the association becoming stronger after adjustment for eGFR (partial ρ = -0.477; p < 0.001). In complementary multivariable models, the inverse association between FGF23 and Glu-OC persisted: Glu-OC was associated with FGF23 (β = −0.258; p = 0.024), along with ALP (β = 0.369; p = 0.001), while FGF23 was associated with Glu-OC (β = −0.266; p = 0.020), along with calcium (β = −0.366; p = 0.002). Conclusion: FGF23 is independently and inversely associated with Glu-OC in non-dialysis CKD, and this relationship persists after adjustment for kidney function. These findings support an association between FGF23 and Glu-OC in CKD–mineral and bone disorder (CKD-MBD).

Article
Medicine and Pharmacology
Urology and Nephrology

Bennur Esen

,

Ahmet Engin Atay

,

Ferdi Karagöz

,

Irfan Şahin

Abstract: In autosomal dominant polycystic kidney disease (ADPKD), arginine vasopressin (AVP) and copeptin, a marker of AVP secretion, play important roles. This study aimed to investigate the associations between coffee consumption, serum copeptin levels, and echocardiographic parameters in patients with ADPKD. The study included 75 patients with ADPKD. Serum copeptin levels were measured, monthly coffee consumption was recorded in g/month, and transthoracic echocardiography was performed. Copeptin levels were lower in coffee consumers (262.73 vs. 331.28 ng/L; p = 0.009) and were inversely correlated with coffee consumption status (r = −0.329; p = 0.008). After adjustment, the negative association between coffee consumption and copeptin levels remained significant (B = −0.284, β = −0.306; p = 0.030). Mitral annular e′ velocity was higher in coffee consumers (0.92 vs. 0.69 m/s; p = 0.029) and was significantly associated with coffee consumption after adjustment (B = 0.226, β = 0.263; p = 0.033). No significant associations were found with eGFR, left ventricular mass index, ejection fraction, or the E/e′ ratio. Coffee consumption was associated with lower copeptin levels and higher e′ velocity. These findings are hypothesis-generating and do not demonstrate causality, further comparative studies are needed to determine whether these associations are specific to ADPKD.

Article
Medicine and Pharmacology
Urology and Nephrology

Hasan Deliağa

,

Büşra Gizem Fırat

,

Öznur Yılmaz Bayer

,

Mete Kaya

Abstract: Background/Objectives: Cryptorchidism occurs in numerous genetic developmental disorders, yet these associations are generally considered syndrome by syndrome, and the biological basis for their recurrence across molecularly heterogeneous conditions remains poorly understood. We aimed to characterize the clinical and molecular findings and develop a hypothesis-generating framework of developmental convergence. Methods: We retrospectively evaluated children with genetically confirmed rare developmental disorders who underwent surgical treatment for cryptorchidism at a tertiary pediatric urology center between 2015 and 2025. Clinical, operative, and molecular data were analyzed at patient and testis levels, and disorder-specific associations with cryptorchidism were evaluated through targeted literature review. Results: Among 94 children screened, 26 met the inclusion criteria, contributing 41 undescended testes. Cryptorchidism was bilateral in 57.7% of patients, 51.2% of testes were nonpalpable, and 51.2% were located at a high inguinal or intra-abdominal level. Despite substantial molecular heterogeneity, the underlying abnormalities could be organized into five interconnected developmental domains involving gene-expression regulation, signal sensing and integration, neural information transmission, neuromuscular execution and fetal mechanobiology, and mesenchymal and structural implementation. Conclusions: We propose that genetically distinct developmental disorders may perturb different levels of the biological system required for testicular descent while converging on shared downstream morphogenetic processes. This developmental-convergence model is hypothesis-generating and provides a testable framework linking human genetics, developmental biology, and pediatric urology.

Article
Medicine and Pharmacology
Urology and Nephrology

Emily Ye

,

Randall G Bissette

,

Mauricio Vassallo

,

Maxwell Sandberg

,

Ashok Hemal

,

Alejandro R. Rodriguez

Abstract: Background/Objectives: Salvage radical prostatectomy (SRP) is a potentially curative option for recurrent localized prostate cancer after primary radiation or focal therapy, historically limited by technical complexity and poor functional outcomes. Advances in robotic surgery have prompted re-evaluation of SRP. This study characterizes contem-porary perioperative, oncologic, and functional outcomes of salvage robotic-assisted radical prostatectomy (sRARP) at a single institution over two decades. Methods: We retrospectively reviewed patients undergoing SRP at our institution from 01/01/2004 to 06/30/2026, identified via combined institutional database query and natural language processing (NLP) keyword search with individual chart confirmation; analysis was re-stricted to the robotic-assisted subset. Clinicodemographic, perioperative, pathologic, and functional data were collected at diagnosis, recurrence, and following SRP, with conti-nence and erectile function also assessed at last follow-up. Descriptive statistics were reported as median (interquartile range, IQR) or n/N (%). Results: Of 4,002 records identified, 30 patients met inclusion criteria; 24 (80%) underwent sRARP. Extraprostatic disease was present in 54% (13/24) and positive margins in 43% (10/23). A postoperative complication occurred in 22% (4% Clavien-Dindo IIIa); bladder neck contracture devel-oped in 18% (4/22), and 8% (2/24) progressed to urinary diversion. At a median follow-up of 32.1 months, 70% (14/20) remained biochemically recurrence-free. Incontinence rose from 18% (3/17) at diagnosis to 83% (19/23) post-SRP; at longer-term follow-up (27.3 months), 79% (11/14) used ≥1 pad/day. Erectile dysfunction was present in 82% (14/17) at a median follow-up of 22.0 months. Additional cancer-control therapy, predominantly androgen deprivation therapy, was given in 33%. No deaths were attributed to an SRP-specific cause. Conclusions: In this study, sRARP achieved perioperative and high-grade complication rates comparable to the broader robotic salvage literature, with a 70% biochemical recurrence-free rate, supporting its role as a potentially curative option in selected patients. A substantial functional burden, particularly incontinence, and se-vere complications including urinary diversion underscore the need for refined patient selection, thorough counseling and further multi-institutional study.

Study Protocol
Medicine and Pharmacology
Urology and Nephrology

Jennifer Kranz

,

Florian M. E. Wagenlehner

,

Laila Schneidewind

Abstract: Background: Radical cystectomy (RC) with urinary diversion is considered the standard treatment for muscle-invasive and selected cases of high-risk non-muscle invasive bladder cancer. As a complex procedure it carries a high risk for complications, especially infectious ones. Orthotopic ileal neobladders (IN) have the highest risk of infectious complications and hospital readmission in comparison to ileal conduits. Unfortunately, the evidence for antibiotic management, including periprocedural prophylaxis and treatment of asymptomatic bacteriuria (ASB) in this special patient cohort is still limited. Furthermore, there is no international consensus on the clinical risk factors that justify intensified antibiotic use, leading to wide practice variability and concerns regarding antimicrobial stewardship. Objective: This Delphi consensus study aims to identify the best antibiotic management, including periprocedural prophylaxis as well as treatment of ASB, and define procedural, patient-related and microbiological risk factors that warrant antibiotic intensified usage in patients with RC and IN and to establish evidence-informed best practice recommendations. Methods: A modified three-round Delphi process will be conducted in accordance with DELPHISTAR guideline. A diverse panel of 30 – 40 international experts in urology, infectious diseases, microbiology, antimicrobial stewardship and medical oncologists will anonymously give recommendations for antibiotic management and evaluate predefined and newly suggested risk factors using a 6-point Likert scale. Consensus will be defined as ≥70% of participants rating an item as highly important (score 5–6) and <15% rating it as unimportant (score 1–2). Items failing to reach consensus in Rounds 1 and 2 will be reevaluated in subsequent rounds. Outcomes: The primary outcomes are consensus-based best practice recommendation for periprocedural antibiotic prophylaxis, antibiotic prophylaxis for catheter removal and definition of ASB as well as antibiotic management of ASB. The secondary outcome will be a consensus-based list of risk factors justifying intensified antibiotic usage in patients with RC and IN. Dissemination: Findings will be submitted for publication in peer-reviewed journals to support global efforts in harmonizing practice and promoting responsible antibiotic use in bladder cancer treatment with RC and IN.

Article
Medicine and Pharmacology
Urology and Nephrology

Veronica Aladzhova

,

Teodora Ilieva

,

Bilyana Vasileva

,

Mariana Petkova

,

Martin Milkinski

,

Simona Kuzmanova-Hrischeva

,

Simona Kerezieva

,

Ina Georgieva

,

Ivan Trendafilov

,

Maria Radanova

+1 authors

Abstract: Background/Objectives: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are established in chronic kidney disease, but evidence in glomerular disease is limited and patients on intensified immunosuppression have been excluded from the randomised trials. We examined the effect of dapagliflozin on proteinuria and kidney function over two years in such a population. Methods: Single-centre retrospective cohort study with historical controls. 147 patients treated with dapagliflozin between 2021 and 2025 were compared with 170 patients seen between 2014 and 2021, most with biopsy-proven glomerular diseases. Proteinuria and estimated glomerular filtration rate (eGFR) were assessed at months 0, 12 and 24, and comparisons used analysis of covariance adjusted for baseline. Subgroups on intensified immunosuppression at entry were prespecified. Results: Proteinuria fell by 51.9% under dapagliflozin and by 22.2% in the historical cohort; the adjusted geometric mean ratio (GMR) was 0.684 (95% CI 0.534–0.877; p = 0.003). During the second year the decline in eGFR was 4.61 mL/min/1.73 m² per year slower under dapagliflozin (95% CI 1.83–7.40; p = 0.001), and an eGFR below 15 mL/min/1.73 m² was reached by 0.7% of treated patients against 11.8% of controls. Among patients on intensified immunosuppression, proteinuria fell by 67.5% when dapagliflozin was added, against 4.6% on the same treatment without it (adjusted GMR 0.371; 95% CI 0.236–0.583; p < 0.001). Conclusions: Dapagliflozin was associated with a progressive antiproteinuric effect, most marked in patients on intensified immunosuppression, and with stabilisation of kidney function. Given the observational design, these magnitudes should be read as an upper bound.

Article
Medicine and Pharmacology
Urology and Nephrology

Junji Uchida

,

Shunji Nishide

,

Yuji Takeyama

,

Taiyo Otoshi

,

Minoru Kato

,

Takeshi Yamasaki

,

Tomoaki Iwai

,

Toshihide Naganuma

,

Katsuyuki Kuratsukuri

Abstract: Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV out-comes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and evero-limus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of base-line. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated re-jection, or antibody-mediated rejection occurred; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.

of 25